News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Introgen Therapeutics, Inc. (INGN) Sell-Off Continues


9/4/2008 11:25:03 AM

Investors extended their retreat from Introgen Therapeutics Inc. for a third day on Thursday following a major blow from the U.S. Food and Drug Administration. On Tuesday Austin-based Introgen announced the FDA had declined to accept its application to market Advexin, the head and neck cancer drug the company has spent more than a decade developing.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES